Advertisement

Dopamine Imaging in Idiopathic Parkinson Disease and Other Parkinsonisms

  • Yen F. Tai
  • Nicola PaveseEmail author
Chapter
Part of the Current Clinical Neurology book series (CCNEU, volume 44)

Abstract

Parkinsonism is clinically characterised by slowed movement, muscle rigidity, tremor at rest and postural instability, along with a variety of non-motor features. Many of these findings are closely linked to the progressive loss of nigrostriatal dopamine neurons. Various methods have been developed to image dopamine in the brain. This chapter will review the various imaging methods and summarise the diagnostic utility of dopamine imaging in idiopathic Parkinson disease (iPD) and other related disorders. Discussion will also provide insights into future applications of dopamine imaging, including its use as a biomarker in clinical trials.

Keywords

Positron Emission Tomography Single Photon Emission Compute Tomography Dementia With Lewy Body Essential Tremor Dopamine Dysregulation Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.PubMedCrossRefGoogle Scholar
  2. 2.
    Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973;20:415–55.PubMedCrossRefGoogle Scholar
  3. 3.
    Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114:2283–301.PubMedCrossRefGoogle Scholar
  4. 4.
    Rice ME, Patel JC, Cragg SJ. Dopamine release in the basal ganglia. Neuroscience. 2011;198:112–37.PubMedCrossRefGoogle Scholar
  5. 5.
    Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson’s disease. Ann Neurol. 2003;53:S110–8; discussion S8–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Snow BJ, Tooyama I, McGeer EG, et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol. 1993;34:324–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry. 1986;49:853–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson’s disease and normal aging. Ann Neurol. 1996;40:873–84.PubMedCrossRefGoogle Scholar
  9. 9.
    Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Ann Neurol. 1995;38:589–98.PubMedCrossRefGoogle Scholar
  10. 10.
    Brucke T, Asenbaum S, Pirker W, et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm-Supp. 1997;50:9–24.CrossRefGoogle Scholar
  11. 11.
    Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord. 2003;18(Suppl 7):S43–51.PubMedCrossRefGoogle Scholar
  12. 12.
    Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson’s disease, studied with PET. Brain. 1990;113 (Pt 5):1539–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? Ann Neurol. 1997;41:58–64.PubMedCrossRefGoogle Scholar
  14. 14.
    Lang AE, Lozano AM. Parkinson’s disease. Second of two parts. N Engl J Med. 1998;339:1130–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson’s disease: a longitudinal 18F-dopa PET study. Neuroimage. 2011;56:1463–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson’s disease A 3D [(18)F]dopa-PET study. Brain. 1999;122 (Pt 9):1637–50.PubMedCrossRefGoogle Scholar
  17. 17.
    Kaasinen V, Nurmi E, Bruck A, et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson’s disease: sex differences in the prefrontal cortex. Brain. 2001;124:1125–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Whone AL, Moore RY, Piccini PP, Brooks DJ. Plasticity of the nigropallidal pathway in Parkinson’s disease. Ann Neurol. 2003;53:206–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol. 2000;47:493–503.PubMedCrossRefGoogle Scholar
  20. 20.
    Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson’s disease. Brain. 2011;134:3290–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson’s disease in the community? J Neurol Neurosurg Psychiatry. 2002;73:529–34.PubMedCrossRefGoogle Scholar
  23. 23.
    Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503–10.PubMedCrossRefGoogle Scholar
  24. 24.
    Marshall VL, Reininger CB, Marquardt M, et al. Parkinson’s disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord. 2009;24:500–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Marek KL, Jennings DL, Seibyl JP, Parkinson Study Group. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology. 2005;64:A274-A.Google Scholar
  26. 26.
    Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord. 2007;22:2210–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990;28:547–55.PubMedCrossRefGoogle Scholar
  28. 28.
    Brooks DJ. PET studies on the early and differential diagnosis of Parkinson’s disease. Neurology. 1993;43:S6–16.PubMedGoogle Scholar
  29. 29.
    Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson’s disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry. 1994;57:278–84.PubMedCrossRefGoogle Scholar
  30. 30.
    Vlaar AM, de Nijs T, Kessels AG, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. European Neurology. 2008;59:258–66.PubMedCrossRefGoogle Scholar
  31. 31.
    Antonini A, Leenders KL, Vontobel P, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson’s disease. Brain. 1997;120(Pt 12):2187–95.PubMedCrossRefGoogle Scholar
  32. 32.
    Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol. 1992;31:184–92.PubMedCrossRefGoogle Scholar
  33. 33.
    Cummings JL. Intellectual impairment in Parkinson’s disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol. 1988;1:24–36.PubMedCrossRefGoogle Scholar
  34. 34.
    Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol. 1996;53:538–42.PubMedCrossRefGoogle Scholar
  35. 35.
    Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology. 2007;68:812–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78:1176–81.PubMedCrossRefGoogle Scholar
  37. 37.
    McKeith I, O’Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13.PubMedCrossRefGoogle Scholar
  38. 38.
    McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863–72.PubMedCrossRefGoogle Scholar
  39. 39.
    Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology. 1993;43:552–6.PubMedCrossRefGoogle Scholar
  40. 40.
    Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord. 2003;18(Suppl 7):S28–33.PubMedCrossRefGoogle Scholar
  41. 41.
    Gerschlager W, Bencsits G, Pirker W, et al. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson’s disease. Mov Disord. 2002;17:518–23.PubMedCrossRefGoogle Scholar
  42. 42.
    Zijlmans J, Evans A, Fontes F, et al. [123I] FP-CIT SPECT study in vascular parkinsonism and Parkinson’s disease. Mov Disord. 2007;22:1278–85.PubMedCrossRefGoogle Scholar
  43. 43.
    Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med. 2004;45:1688–93.PubMedGoogle Scholar
  44. 44.
    Benaderette S, Zanotti Fregonara P, Apartis E, et al. Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. Mov Disord. 2006;21:310–7.PubMedCrossRefGoogle Scholar
  45. 45.
    de la Fuente-Fernandez R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology. 2012;78:696–701.PubMedCrossRefGoogle Scholar
  46. 46.
    Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson’s disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45:577–82.PubMedCrossRefGoogle Scholar
  47. 47.
    Khan NL, Scherfler C, Graham E, et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology. 2005;64:134–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Hilker R, Klein C, Hedrich K, et al. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett. 2002;323:50–4.PubMedCrossRefGoogle Scholar
  49. 49.
    Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol. 2004;56:173–81.PubMedCrossRefGoogle Scholar
  50. 50.
    Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson’s disease and evidence for presymptomatic compensation. Brain. 2005;128:2777–85.PubMedCrossRefGoogle Scholar
  51. 51.
    Nandhagopal R, Mak E, Schulzer M, et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology. 2008;71:1790–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol. 1994;36:759–64.PubMedCrossRefGoogle Scholar
  53. 53.
    Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Nurmi E, Ruottinen HM, Bergman J, et al. Rate of progression in Parkinson’s disease: a 6-[18F]fluoro-L-dopa PET study. Mov Disord. 2001;16:608–15.PubMedCrossRefGoogle Scholar
  55. 55.
    Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson’s disease: a multi-tracer positron emission tomography study. Brain. 2009;132:2970–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol. 2005;62:378–82.PubMedCrossRefGoogle Scholar
  57. 57.
    Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93–101.PubMedCrossRefGoogle Scholar
  58. 58.
    Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. J Am Med Assoc. 2002;287:1653–61.CrossRefGoogle Scholar
  59. 59.
    Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–508.PubMedCrossRefGoogle Scholar
  60. 60.
    Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Science. 1990;247:574–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9:589–95. (Epub 2003 Mar 31).Google Scholar
  62. 62.
    Breier A, Su TP, Saunders R, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A. 1997;94:2569–74.PubMedCrossRefGoogle Scholar
  63. 63.
    Tedroff J, Pedersen M, Aquilonius SM, Hartvig P, Jacobsson G, Langstrom B. Levodopa-induced changes in synaptic dopamine in patients with Parkinson’s disease as measured by [11C]raclopride displacement and PET. Neurology. 1996;46:1430–6.PubMedCrossRefGoogle Scholar
  64. 64.
    de la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson’s disease: PET evidence of increased dopamine turnover. Ann Neurol. 2001;49:298–303.PubMedCrossRefGoogle Scholar
  65. 65.
    de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain. 2004;127:2747–54. (Epub 2004 Aug 25).PubMedCrossRefGoogle Scholar
  66. 66.
    Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology. 2006;67:1612–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol. 2006;59:852–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain. 2009;132:1376–85.PubMedCrossRefGoogle Scholar
  69. 69.
    O’Sullivan SS, Wu K, Politis M, et al. Cue-induced striatal dopamine release in Parkinson’s disease-associated impulsive-compulsive behaviours. Brain. 2011;134:969–78.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of NeurologyImperial College Healthcare NHS TrustLondonUK
  2. 2.Centre for Neuroscience, Hammersmith Hospital CampusImperial College LondonLondonUK

Personalised recommendations